Prime Medicine (PRME) Non-Current Deffered Revenue (2024 - 2026)

Prime Medicine (PRME) has 3 years of Non-Current Deffered Revenue data on file, last reported at $57.8 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 4.75% year-over-year to $57.8 million; the trailing twelve-month figure through Mar 2026 stood at $57.8 million (down 4.75% YoY), and the FY2025 full-year result was $58.1 million, down 8.05% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $57.8 million, down from $58.1 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $63.2 million in Q4 2024 and bottomed at $57.8 million in Q1 2026.
• The 3-year median for Non-Current Deffered Revenue is $59.8 million (2025), against an average of $60.2 million.
• Peak annual rise in Non-Current Deffered Revenue reached 4.61% in 2025, while the deepest fall reached 8.05% in 2025.
• A 3-year view of Non-Current Deffered Revenue shows it stood at $63.2 million in 2024, then declined by 8.05% to $58.1 million in 2025, then fell by 0.61% to $57.8 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $57.8 million (Q1 2026), $58.1 million (Q4 2025), and $59.8 million (Q3 2025), per Business Quant data.

Peer Comparison